Actively Recruiting
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-05-07
60
Participants Needed
1
Research Sites
92 weeks
Total Duration
On this page
Sponsors
F
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead Sponsor
U
University of Rome Tor Vergata
Collaborating Sponsor
AI-Summary
What this Trial Is About
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.
CONDITIONS
Official Title
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with medulloblastoma who were operated on at the Pediatric Neurosurgery Unit during their pediatric age
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione Policlinico Gemelli Irccs
Roma, ROMA, Italy, 00151
Actively Recruiting
Research Team
G
GIANPIERO TAMBURRINI, MD
CONTACT
M
MARIA CONCETTA GELOSO, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here